Tirzepatide 15mg

Description

Tirzepatide 15mg — Research Dual Incretin Agonist (GLP-1 / GIP)

Tirzepatide 15mg is a dual incretin research peptide that simultaneously targets both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. Furthermore, this dual-pathway mechanism makes Tirzepatide 15mg a highly valuable compound for advanced metabolic and endocrine research studies.

Research Focus (Non-Clinical)

Researchers primarily deploy to investigate GLP-1R and GIPR receptor co-activation pathways. In addition, preclinical studies examine its role in glucose homeostasis, insulin sensitivity markers, and energy expenditure endpoints. Moreover, investigators use this peptide to study visceral adiposity reduction models and lipid metabolism under controlled laboratory conditions.

Product Specifications

Each vial contains 15mg of lyophilized Tirzepatide, ensuring maximum stability during storage and handling. Therefore, researchers benefit from accurate dosing and consistent batch-to-batch quality. NUPEPS Peptides verifies every batch for identity and purity through rigorous third-party lab testing.

Regulatory & Use

Tirzepatide 15mg is strictly for laboratory research purposes only. It is not intended for human, veterinary, or diagnostic use. Qualified researchers can also review the full COA Library for batch-specific purity data.